Patent intelligence · US
US 9345718
Phospholipid ether analogs as cancer-targeting drug vehicles
Phospholipid ether analogs as cancer-targeting drug vehicles
Patent details — US 9345718
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2016
- Expiration
- May 19, 2036
- Applicant
- CELLECTAR BIOSCIENCES, INC.
- Claims
- 2
- CPC classes
- A61K, A61K31/00, A61K31/337, A61K31/395
Quick answer
US 9345718 (Phospholipid ether analogs as cancer-targeting drug vehicles) is held by CELLECTAR BIOSCIENCES, INC.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CELLECTAR BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/00, A61K31/337, A61K31/395, A61K31/537, A61K31/665
More from CELLECTAR BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11439709
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9925269
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9616140
Fluorescent phospholipid ether compounds, compositions, and methods of use
granted -
US 9579406
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
granted -
US 9550002
Phospholipid analogs as diapeutic agents and methods thereof
granted -
US 9480754
Phospholipid ether analogs as cancer-targeting drug vehicles
granted
Related coverage
Frequently asked questions
What is US patent 9345718?
US 9345718 (Phospholipid ether analogs as cancer-targeting drug vehicles) is held by CELLECTAR BIOSCIENCES, INC.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9345718?
CELLECTAR BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9345718 expire?
Our index shows an expiration date of May 19, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.